Heart failure drug trial pulled before it even started

NCT ID NCT05953831

Terminated Disease control Sponsor: Cardior Pharmaceuticals GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This was a planned Phase 2 study testing a drug called CDR132L in about 130 people with heart failure and a preserved or mildly reduced ejection fraction. The drug aimed to reverse harmful changes in the heart muscle. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDR132L (a synthetic molecule that blocks a specific microRNA linked to heart damage)
What this could lead to: If successful, this could point toward a treatment that reverses heart muscle thickening and improves heart function in certain types of heart failure.
What could go wrong: This trial was withdrawn before enrolling any participants, so no data exists yet. Even if tested, early-phase studies often fail to show benefit in larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cardiomegaly diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

More trials for these conditions

Other studies related to the condition(s) this trial covers.